Vedolizumab for inflammatory bowel diseasesI
Aim of review. To present literature data on administration of vedolizumab at inflammatory bowel diseases. Summary. The vedolizumab is anti-α4β7-integrin humanized class IgG1 antibodies which suppresses migration of leukocytes in intestinal tissue, interfering thereby with development of pathol...
Saved in:
Main Authors: | Igor L. Khalif, M. V. Shapina |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Gastro LLC
2018-08-01
|
Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
Subjects: | |
Online Access: | https://www.gastro-j.ru/jour/article/view/99 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chronic inflammatory bowel diseases: the course and treatment methods in Russian Federation (Results of multicenter population-based one-stage observational study)
by: L. . Khalif, et al.
Published: (2018-08-01) -
Noninvasive markers of inflammatory bowel disease activity
by: A. V. Nikitin, et al.
Published: (2018-08-01) -
Extraintestinal manifestations of inflammatory bowel diseases: arthropathy and arthritis
by: Gulustan Hamid Sadygova
Published: (2018-08-01) -
Safety and efficacy of total colectomy with D3 lymph node dissection at colorectal cancer, developed at inflammatory bowel diseases (case control study)
by: P. V. Tsarkov, et al.
Published: (2018-08-01) -
Colonic cytokines for severe ulcerative colitis
by: Ye. A. Konovich, et al.
Published: (2016-08-01)